Off-Label Promotion Ruling Increases Pressure For FDA Policy Change

Amarin Corp. PLC's First Amendment legal victory on Vascepa (icosapent ethyl) may intensify pressure on FDA to develop new guidance and regulations governing off-label promotion before its hand is further forced by more adverse court rulings and Congress.